WS Investor
03 Feb 2026, 22:53
Pfizer Inc. reported solid full-year 2025 results and reaffirmed its full-year 2026 financial guidance, highlighting strong execution and continued progress in its late-stage pipeline.
Pfizer generated full-year 2025 revenues of $62.6 billion, representing a 2% year-over-year operational decline, while revenues excluding COVID-19 products Paxlovid and Comirnaty grew 6% operationally. Reported diluted EPS for the year was $1.36, with adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues totaled $17.6 billion, down 3% operationally year over year, while adjusted diluted EPS came in at $0.66.
The company reaffirmed its 2026 outlook, maintaining revenue guidance of $59.5–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00. Pfizer also emphasized pipeline momentum, with 11 key pivotal studies initiated in 2025 and approximately 20 pivotal study starts planned for 2026.
Source: Pfizer Inc. press release
Pfizer generated full-year 2025 revenues of $62.6 billion, representing a 2% year-over-year operational decline, while revenues excluding COVID-19 products Paxlovid and Comirnaty grew 6% operationally. Reported diluted EPS for the year was $1.36, with adjusted diluted EPS of $3.22. Fourth-quarter 2025 revenues totaled $17.6 billion, down 3% operationally year over year, while adjusted diluted EPS came in at $0.66.
The company reaffirmed its 2026 outlook, maintaining revenue guidance of $59.5–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00. Pfizer also emphasized pipeline momentum, with 11 key pivotal studies initiated in 2025 and approximately 20 pivotal study starts planned for 2026.
Source: Pfizer Inc. press release